The ambitious plan outlines the strategy of the Access to Covid-19 Tools Accelerator (ACT-A) until September 2022, expected to include use of an experimental oral antiviral pill made by Merck & Co for treating mild and moderate cases.
If the pill is approved by regulatory authorities, the cost could be as little as $10 per course, the plan said, in line with a draft document nL1N2RF1BE seen by Reuters earlier this month.
“The request is for $23.4 billion. That’s a fair amount of money, but if you compare with the damage also done to global economy by the pandemic it is not really that much,” Carl Bildt, WHO Special Envoy to the ACT-Accelerator, told a pre-briefing for selected journalists ahead of a press conference by WHO Director-General Tedros Adhanom Ghebreyesus.
Bildt, a former prime minister of Sweden, acknowledged that the ACT-A has struggled to secure previous financing and noted that Norway and South Africa co-chair a fund-raising effort.
“So we do expect a strong signal from (the G20) coming out of the meeting in Rome over the weekend,” he said.
Equal budgets of $7 billion are earmarked for both vaccines and diagnostic tests, with a further $5.9 billion for boosting health systems and $3.5 billion for treatments including antivirals, corticosteroids, and medical oxygen.
Covax, the vaccines arm of the ACT-A, has delivered some 400 million Covid-19 doses to more than 140 low- and middle-income countries, where vaccination rates remain low, WHO chief scientist Soumya Swaminathan said.
“We know there are about 30 countries that are dependent on Covax alone, they have no other source of vaccines,” she said.
About 82 countries are likely to miss a WHO global target of 40% vaccination coverage by year-end, but some of them could if supplies start flowing, she said.
Referring to India which resumed “relatively modest” Covid-19 vaccine exports this month after suspending them in April due to its domestic epidemic, Swaminathan said: “I think these volumes coming out of India will go up significantly.”
She added: “One of the things that is now interfering in a big way is the need for boosters, more and more high income countries are going in for the booster doses and this is now sucking up the vaccine doses as well.”
Credit: Source link